6 juill. 2017 - The JAMA Viewpoint article by Dr. Scott Gottlieb and Dr. Janet Woodcock entitled, “Marshaling FDA Benefit-Risk Expertise to Address the Current Opioid Abuse Epidemic," was published. Following the FDA’s request, Endo announced that it would voluntarily remove reformulated Opana ER from the market.
Ajouté au bande de temps:
Date:
6 juill. 2017
Maintenaint
~ Il y a 8 ans et 3 mois